Vortex Energy Quote - VRTX

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.055

Bid

0.055

Offer

0.06

Volume

54,550

0.055 Day's Range 0.06

0.055 52 Week Range 0.85

Previous Close

0.055

Open

0.06

Last Trade

10000

0.055

Last Trade Time

Average Volume (3m)

129,877

Financial Volume

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.005	-8.33333333333	0.06	0.065	0.055	139302	0.05613782	CS
4	-0.04	-42.1052631579	0.095	0.095	0.055	175217	0.06428399	CS
12	-0.09	-62.0689655172	0.145	0.145	0.055	129877	0.08870519	CS
26	-0.155	-73.8095238095	0.21	0.27	0.055	85998	0.12396922	CS
52	-0.345	-86.25	0.4	0.85	0.055	154689	0.3749406	CS
156	-0.045	-45	0.1	2.32	0.055	200389	0.92344865	CS
260	-0.045	-45	0.1	2.32	0.055	200389	0.92344865	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CODECypher Metaverse Inc	$ 0.70 (536.36%)	24.75k
ALEAlerio Gold Corp	$ 0.015 (200.00%)	61k
AUMCAuric Minerals Corp	$ 0.98 (145.00%)	149.71k
SLZSlave Lake Zinc Corp	$ 0.02 (100.00%)	13.5k
TUGATuga Innovations Inc	$ 0.01 (100.00%)	24k
CVGRCity View Green Holdings Inc	$ 0.005 (-50.00%)	2.2M
CACR.AKWG Resources Inc	$ 1.35 (-41.56%)	400
TTXTantalex Lithium Resources Corporation	$ 0.015 (-40.00%)	253k
VLTAVolta Metals Ltd	$ 0.025 (-37.50%)	7k
UAVGlobal UAV Technologies Ltd	$ 0.14 (-36.36%)	2k
PKKPeak Fintech Group Inc	$ 0.105 (-19.23%)	4.55M
CLDVCloud3 Ventures Inc	$ 0.015 (0.00%)	2.4M
CVGRCity View Green Holdings Inc	$ 0.005 (-50.00%)	2.2M
MAXXMax Power Mining Corp	$ 0.205 (-8.89%)	1.75M
GRUVProtium Clean Energy Corp	$ 0.05 (-16.67%)	1.74M